Co-Diagnostics, Inc. Liquidation Value

CODX Medical Devices

Cash & Equivalents

$8.23M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $8.23M
Total Obligations: -$7.49M
$743,314
Per share: $0.21
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $8.23M
AR: $82,339
Total Obligations: -$7.49M
$825,653
Per share: $0.23
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $8.23M
AR: $82,339
Inventory: $846,119
Total Obligations: -$7.49M
$1.67M
Per share: $0.46
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$743,314$0.21
Liquid Liquidation Value$825,653$0.23
Operating Liquidation Value$1.67M$0.46

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-14. View on SEC EDGAR →

Cash & Equivalents$8.23M
Accounts Receivable$82,339
Inventory$846,119
Current Liabilities$4.28M
Long-term Debt (?)N/A
Op. Lease Liability (?)$1.17M
Finance Lease (?)N/A
Shares Outstanding3.6M

Explore all 108 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$8.23M$82,339$846,119$2.02M$4.28MN/A$1.17MN/A
2025-12-31$11.88M$190,375$992,397$1.88M$3.54MN/A$574,301N/A
2025-09-30$11.44M$55,905$1.09M$1.46M$3.69MN/A$727,943N/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-14 View
2025-12-31 10-K 2026-03-31 View
2025-09-30 10-Q 2025-11-13 View
2025-06-30 10-Q 2025-08-14 View
2025-03-31 10-Q 2025-05-08 View
2024-12-31 10-K 2025-03-27 View
2024-09-30 10-Q 2024-11-07 View
2024-06-30 10-Q 2024-08-08 View

AI Insights

AI Insight·Generated 2026-05-15

Co-Diagnostics, Inc. (CODX) presents a precarious liquidation posture as of March 31, 2026. The balance sheet is dominated by cash and a large in-process R&D intangible, with negligible operating assets. Under liquidation lens: cash of $8.2M recovers at par; net AR of $82K recovers at approximately $74K-$78K (90-95% haircut); net inventory of $846K recovers at approximately $508K (60% haircut); the $7.2M in-process R&D intangible carried at cost with indefinite life recovers at $0 under standard liquidation assumptions (no amortization, no market, pre-revenue). PP&E and ROU assets are not separately quantifiable from the truncated XBRL tag set but the filing discloses $2.0M in operating lease liabilities (present value) that must be settled at face value on windup. Total operating lease payments due are $2.18M through 2028. Reported total stockholders' equity of $16.0M is substantially overstated relative to liquidation recovery because it includes $7.2M of intangibles that zero out. Adjusted liquidation equity is roughly $8.8M minus operating lease liabilities ($2.0M) minus other current liabilities (the filing references total current liabilities of $4.3M) minus the $7.2M intangible write-off, implying negative to marginally positive recovery to equity depending on the composition of current liabilities and any unlisted accruals. The company has disclosed substantial doubt about going concern for 12 months from filing date, consistent with $9.1M net loss in Q1 2026, cash burn of $7.8M from operations in the quarter, and the ATM facility effectively shut down after the S-3 registration statement expired April 6, 2026. Cash dropped from $11.9M at December 31, 2025 to $8.2M at March 31, 2026 — a $3.7M net decline in one quarter despite $4.6M in ATM proceeds. No debt instruments are disclosed. Contingent consideration liability (Level 3, common stock) stands at $43.8K and is de minimis. Inventory reserves increased materially QoQ ($155K recognized in Q1 2026 vs. $41K in Q1 2025), signaling accelerating obsolescence of raw materials and finished goods. The filing discusses operating lease right-of-use assets obtained of $1.03M in Q1 2026 (new lease entered during quarter per cash flow disclosure), which adds to the ASC 842 liability stack — this is discussed in the notes but the specific ROU asset balance is not separately tagged in XBRL. PP&E is not separately tagged. The prior filing (10-K for FY2025) shows stockholders' equity of $20.6M at December 31, 2025, which declined to $16.0M by March 31, 2026 — a $4.6M deterioration in one quarter driven by the $9.1M net loss partially offset by $4.3M in ATM equity issuance. The $89.5M accumulated deficit at period end confirms the entity has consumed equity at scale historically.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...